RE: Drug Discovery Collaboration Agreement dated September 13, 2002 - Exercise of Option to Extend Funding of Research FTEs

Collaboration Agreement

You are currently viewing:

This Collaboration Agreement involves

ARRAY BIOPHARMA INC

. RealDealDocs™ contains millions of easily searchable legal documents and clauses from top law firms. Search for free - click here.

Title: RE: Drug Discovery Collaboration Agreement dated September 13, 2002 - Exercise of Option to Extend Funding of Research FTEs
Date: 11/6/2006
Industry: BIOTRX Sector: HEALTH

Search Collaboration Agreement by:

Exhibit 10 Exhibit 10.6

August 31, 2006

VIA FAX AND FEDERAL EXPRESS

David L. Snitman, Ph.D.

Chief Operating Officer

Array BioPharma, Inc.

3200 Walnut Street Boulder, CO 80301

RE:

Drug Discovery Collaboration Agreement dated September 13, 2002 Exercise of Option to Extend Funding of Research FTEs

Dear Dr. Snitman:

As you know, InterMune, Inc. ("InterMune") and Array BioPharma Inc. ("Array") are parties to that certain Drug Discovery Collaboration Agreement dated September 13, 2002, as amended by Amendment No.1 dated May 8, 2003, Amendment No.2 dated January 7, 2004, Amendment No.3 dated September 10, 2004, Amendment No.4 dated December 7, 2004, Amendment No.5 dated June 30, 2005, Amendment No.6 dated February 3, 2006 and effective January 1, 2006, and Amendment No. 7 dated June 28, 2006 (collectively, the "Agreement"). Any capitalized term contained herein and not otherwise defined herein shall have the meaning ascribed to such term in the Agreement.

Section 5.1.1 of the Agreement provides that the Research FTEs will be funded by InterMune through August 31, 2006 but that InterMune has an option to extend such funding for an additional six (6) month period. InterMune is hereby notifying Array that it is exercising its option such that the funding of the Research FTEs will now be funded t